Market Overview

Sterne Agee Feels More Positive On Allergan Following Recent Call With CEO


In a report published Monday, Sterne Agee analyst Shibani Malhotra reiterated a Buy rating and $185.00 price target on Allergan (NYSE: AGN).

In the report, Sterne Agee noted, “We held a call with Allergan's CEO David Pyott, that left us even more convinced that management's actions are motivated by the desire to maximize shareholder value rather to keep Allergan an independent company. That said, we do believe Allergan will take near term actions that shareholders should value, thus increasing its chance of remaining independent. We remain buyers of AGN given our confidence that this team will drive further shareholder value.”

Allergan closed on Friday at $173.95.

Latest Ratings for AGN

Feb 2020MaintainsBuy
Jan 2020DowngradesOverweightEqual-Weight
Nov 2019DowngradesBuyNeutral

View More Analyst Ratings for AGN
View the Latest Analyst Ratings

Posted-In: Shibani Malhotra Sterne AgeeAnalyst Color Reiteration Analyst Ratings


Related Articles (AGN)

View Comments and Join the Discussion!

Latest Ratings

View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Daily Analyst Rating
A summary of each day’s top rating changes from sell-side analysts on the street.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at